MedTrace Logo

Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST

NCT00331721 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2008-05-22

No results posted yet for this study

Summary

The main objective of this study is to investigate the tolerability of enecadin in patients with acute ischemic stroke. Furthermore, the pharmacokinetics of enecadin in both male and female patients with acute ischemic stroke will be assessed. Efficacy trends will be evaluated up to day 30 post stroke.

Conditions

Interventions

DRUG

Enecadin

Dose escalating

DRUG

Placebo

Placebo comparator

Sponsors & Collaborators

  • PAION Deutschland GmbH

    lead INDUSTRY

Principal Investigators

  • Peter A Ringleb, Dr. · Heidelberg University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Austria
  • Belgium
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00331721 on ClinicalTrials.gov